Dive Brief:

潜水简介：

Eisai has agreed to a new deal with longtime Alzheimer’s disease partner BioArctic, signing up for a “research evaluation” of a preclinical drug designed to more effectively reach the brain. Announced Saturday, the agreement gives Eisai rights to license the drug, called BAN2802, after reviewing data from the collaboration..

卫材已同意与阿尔茨海默病长期合作伙伴BioArctic达成一项新协议，签署了一项旨在更有效地到达大脑的临床前药物的“研究评估”。该协议于周六宣布，在审查了合作数据后，卫材有权对这种名为BAN2802的药物进行许可。。

The drug uses a technology BioArctic calls “BrainTransporter,” which is meant to get antibody drugs past a biological gateway between the blood and brain. This blood-brain barrier often limits how drugmakers can treat diseases like Alzheimer’s and brain cancer.

该药物使用BioArctic称为“脑转运蛋白”的技术，该技术旨在使抗体药物通过血液和大脑之间的生物通道。这种血脑屏障通常限制了制药商如何治疗阿尔茨海默病和脑癌等疾病。

Begun in 2005, the Eisai-BioArctic partnership yielded the Food and Drug Administration-approved drug Leqembi. While study results for Leqembi showed a modest cognitive benefit, the drug has still struggled to make headway, earning only about $10 million last year as patient and physician adoption has been slow..

从2005年开始，卫材生物RCTIC合作伙伴关系产生了美国食品和药物管理局批准的药物Leqembi。虽然Leqembi的研究结果显示出适度的认知益处，但该药物仍在努力取得进展，由于患者和医生的采用缓慢，去年仅获得约1000万美元的收入。。

Dive Insight:

潜水洞察：

Leqembi and the leading experimental drugs for Alzheimer’s are designed around the hypothesis that clumps of a sticky protein called amyloid lead to the cognitive decline seen in the disease. These drugs are synthetic antibodies that bind to amyloid in order to keep it from accumulating in the brain..

Leqembi和治疗阿尔茨海默氏病的主要实验药物是围绕一种称为淀粉样蛋白的粘性蛋白质团块导致该疾病认知能力下降的假设设计的。这些药物是与淀粉样蛋白结合的合成抗体，以防止淀粉样蛋白在大脑中积累。。

While early experimental drugs like Lilly’s solanezumab blocked amyloid in the blood and cerebrospinal fluid, Leqembi and donanemab target and remove amyloid from brain lesions. Antibodies that can penetrate the blood-brain barrier could remove more amyloid, or they could allow doctors to reduce how much medicine they use so patients receive smaller or less frequent doses — potentially limiting side effects..

虽然早期的实验药物如礼来的solanezumab可以阻断血液和脑脊液中的淀粉样蛋白，但Leqembi和donanemab可以靶向并去除大脑病变中的淀粉样蛋白。可以穿透血脑屏障的抗体可以去除更多的淀粉样蛋白，或者可以让医生减少用药量，从而使患者接受较小或较不频繁的剂量-可能会限制副作用。。

Roche is using its own brain transport technology to more effectively deliver its drug gantenerumab, which on its own failed to help people with Alzheimer’s in testing.

罗氏公司正在利用自己的大脑运输技术更有效地提供其药物甘特尼单抗，而甘特尼单抗本身未能帮助阿尔茨海默氏病患者进行测试。

The combined treatment, which Roche now calls trontinemab, has shown promise in a small, early-stage trial. It was able to reduce many patients’ amyloid below detectable levels in 12 weeks, which the company called “best-in-class” potential.

罗氏现在称之为trontinemab的联合治疗在一项小型早期试验中显示出前景。它能够在12周内将许多患者的淀粉样蛋白降低到可检测水平以下，该公司称之为“同类最佳”潜力。

While Leqembi hasn’t yet proved lucrative on the market, its successful development has been a boon for BioArctic. The company last year reported revenue of 616 million Swedish krona, or about $56 million, most of which was related to Leqembi-related milestone payments. The cash influx helped BioArctic turn a profit..

虽然Leqembi尚未在市场上证明有利可图，但它的成功开发对BioArctic来说是一个福音。该公司去年报告收入为6.16亿瑞典克朗，约5600万美元，其中大部分与Leqembi相关的里程碑付款有关。现金流入帮助BioArctic实现了盈利。。

Leqembi could face new competition soon. Eli Lilly’s experimental drug donanemab is awaiting an FDA approval decision, although the agency has delayed it because it wants to call an advisory committee to review certain aspects of its clinical trials.

Leqembi可能很快面临新的竞争。礼来公司的实验药物多纳单抗正在等待FDA的批准决定，尽管该机构推迟了批准决定，因为它想召集一个咨询委员会来审查其临床试验的某些方面。